Industry Veterans Bring 360o Insight to Developing Managed Market Solutions for Stakeholders HealthSTAR Communications, a leading healthcare communications company, today announced the formation of HEALTHSTAR Market Access, LLC, a ...
Daiichi Sankyo Company has decided to expand its collaborative drug discovery program with universities and research institutions based in Japan, Take a New challenge for Drug diScovery (TaNeDS) Global Program, to Germany, Switzerland and ...
Tags: Daiichi Sankyo, Medicine
American Regent, a subsidiary of a Daiichi Sankyo Group Company named Luitpold Pharmaceuticals, has won USFDA approval for Injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency anemia (IDA). A parenteral iron ...
Tags: Iron Deficiency Anemia, Medicine
Daiichi Sankyo Espha, Japan-based generics subsidiary of Daiichi Sankyo, has launched three new generic drugs, Pramipexole hydrochloride 0.125mg tablets DSEP, Pramipexole hydrochloride 0.5mg tablets DSEP and Amlodipine 10mg tablets DSEP, ...
Daiichi Sankyo Company is seeking approval for an oral antiplatelet agent prasugrel hydrochloride to treat ischemic heart diseased patients undergoing percutaneous coronary intervention (PCI) in Japan. The company has submitted a new drug ...
Tags: Daiichi Sankyo, Medicine
Daiichi Sankyo Company has launched Pralia subcutaneous injection 60mg syringe (generic name denosumab) for the treatment of osteoporosis, following its manufacturing and marketing approval in Japan. Designed to specifically inhibit an ...
Tags: Daiichi Sankyo, Syringe
Daiichi Sankyo Company has filed a supplemental new drug application for extended indication of anticancer agent Topotecin intravenous drip infusion 40mg, 100mg with the Japan's Ministry of Health, Labor and Welfare. Topotecin intravenous ...
Japan-based Daiichi Sankyo Company has introduced Denotas chewable combination tablets with calcium/natural vitamin D3/magnesium in the country. Calcium, natural vitamin D3, magnesium are present as precipitated calcium ...
Daiichi Sankyo Pharmaceutical has launched silodosin for the treatment of dysuria associated with benign prostatic hyperplasia in China. Silodosin works by inhibiting the alpha 1A-adrenergic receptor and relieving tension in the prostate, ...
Tags: Daiichi Sankyo, Dysuria Therapy
Daiichi Sankyo Company and Ranbaxy Laboratories have announced synergistic collaboration in Brazil to expand their respective businessess in the country. As part of the synergy, the companies will launch hybrid business model. Ranbaxy ...
Tags: Daiichi Sankyo Company, Medicine
Daiichi Sankyo Company has opened the Orphan Disease Treatment Institute office inside the Daiichi Sankyo Shinagawa R&D center. Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital, and Daiichi Sankyo have ...
Tags: Daiichi Sankyo, Orphan Disease Treatment, Orphan Disease
U3 Pharma, an antibody targeted cancer drug development affiliate of Daiichi Sankyo, has signed a research collaboration deal with AbCheck. AbCheck's commercial multi antibody discovery platforms include AbSieve, which combines the ...
Daiichi Sankyo Company and Ranbaxy Laboratories have announced plans to combine business operations in Thailand. Both the companies plan to integrate the management of Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy Unichem (RUCL), the ...
Tags: Daiichi Sankyo, Ranbaxy, Hybrid Business
Daiichi Sankyo and Amplimmune have collaborated to develop AMP-110 therapeutic protein for the treatment of autoimmune diseases. The companies expect to commence Phase 1 study of the AMP-110 immune modulation therapy, which targets ...
Tags: Daiichi Sankyo, Amplimmune, therapeutic protein, autoimmune diseases
Daiichi Sankyo has gained FDA approval to package product at its packaging facility located in Bethlehem, Pennsylvania, US. The Pennsylvania facility will package some of the company's products for cardiovascular and metabolic ...
Tags: FDA, medical product, expansion, business operations